tradingkey.logo

Evolus Inc

EOLS
6.560USD
-0.620-8.64%
Close 11/07, 16:00ETQuotes delayed by 15 min
424.87MMarket Cap
LossP/E TTM

Evolus Inc

6.560
-0.620-8.64%

More Details of Evolus Inc Company

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.

Evolus Inc Info

Ticker SymbolEOLS
Company nameEvolus Inc
IPO dateFeb 08, 2018
CEOMr. David Moatazedi
Number of employees332
Security typeOrdinary Share
Fiscal year-endFeb 08
Address520 Newport Center Dr Ste 1200
CityNEWPORT BEACH
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92660-7022
Phone19492844555
Websitehttps://www.evolus.com/
Ticker SymbolEOLS
IPO dateFeb 08, 2018
CEOMr. David Moatazedi

Company Executives of Evolus Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
265.91K
+9.47%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
104.60K
--
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
81.27K
+58.52%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
33.96K
-14.80%
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--

Revenue Breakdown

No Data
No Data
By Business
By Region
No Data

Shareholding Stats

Updated: Sat, Aug 23
Updated: Sat, Aug 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
7.71%
Nantahala Capital Management, LLC
6.48%
Lynch (Timothy Patrick)
6.32%
BlackRock Institutional Trust Company, N.A.
5.63%
The Vanguard Group, Inc.
5.27%
Other
68.59%
Shareholders
Shareholders
Proportion
Tang Capital Management, LLC
7.71%
Nantahala Capital Management, LLC
6.48%
Lynch (Timothy Patrick)
6.32%
BlackRock Institutional Trust Company, N.A.
5.63%
The Vanguard Group, Inc.
5.27%
Other
68.59%
Shareholder Types
Shareholders
Proportion
Hedge Fund
38.18%
Investment Advisor
25.41%
Investment Advisor/Hedge Fund
15.74%
Individual Investor
8.47%
Private Equity
7.59%
Corporation
3.30%
Research Firm
1.99%
Bank and Trust
0.56%
Pension Fund
0.56%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
365
58.53M
90.34%
+162.34K
2025Q2
362
58.85M
90.98%
-2.31M
2025Q1
367
61.71M
95.75%
-6.80M
2024Q4
349
59.00M
93.18%
-8.33M
2024Q3
345
58.57M
92.95%
-9.62M
2024Q2
337
59.72M
95.46%
-6.66M
2024Q1
324
57.99M
95.42%
-6.59M
2023Q4
309
53.87M
93.36%
-7.99M
2023Q3
309
51.63M
90.65%
-8.83M
2023Q2
309
53.08M
93.27%
-5.08M
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Tang Capital Management, LLC
5.00M
7.73%
--
--
Jun 30, 2025
Nantahala Capital Management, LLC
4.20M
6.49%
+546.58K
+14.97%
Jun 30, 2025
Lynch (Timothy Patrick)
4.09M
6.33%
+4.09M
--
Aug 11, 2025
BlackRock Institutional Trust Company, N.A.
3.65M
5.64%
-175.30K
-4.58%
Jun 30, 2025
The Vanguard Group, Inc.
3.31M
5.11%
+84.18K
+2.61%
Jun 30, 2025
Caligan Partners, LP
3.34M
5.17%
+610.82K
+22.36%
Jun 30, 2025
Perceptive Advisors LLC
2.47M
3.83%
-1.65M
-40.06%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
2.44M
3.77%
+2.44M
--
Jun 30, 2025
Medy Tox Inc
2.14M
3.3%
-1.24M
-36.82%
Dec 31, 2024
Soleus Capital Management, L.P.
2.12M
3.28%
+1.04M
+96.36%
Jun 30, 2025
View more

Related ETFs

Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
SPDR S&P Pharmaceuticals ETF
0.85%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.64%
iShares U.S. Pharmaceuticals ETF
0.15%
iShares Micro-Cap ETF
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
Proshares Ultra Russell 2000
0.01%
View more
SPDR S&P Pharmaceuticals ETF
Proportion0.85%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion0.64%
iShares U.S. Pharmaceuticals ETF
Proportion0.15%
iShares Micro-Cap ETF
Proportion0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI